| 9.99 0.8 (8.71%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.62 | 1-year : | 14 |
| Resists | First : | 10.8 | Second : | 11.98 |
| Pivot price | 10.18  |
|||
| Supports | First : | 8.89 | Second : | 7.4 |
| MAs | MA(5) : | 9.33 |
MA(20) : | 10.23 |
| MA(100) : | 10.72 |
MA(250) : | 11.33 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 19.8 |
D(3) : | 10.4 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 15.47 | Low : | 8.06 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLSI ] has closed above bottom band by 44.0%. Bollinger Bands are 86.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.02 - 10.06 | 10.06 - 10.11 |
| Low: | 9.23 - 9.28 | 9.28 - 9.33 |
| Close: | 9.9 - 9.99 | 9.99 - 10.07 |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Thu, 09 Oct 2025
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Clinical Trial to Austria - Quiver Quantitative
Thu, 09 Oct 2025
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial - Stock Titan
Thu, 02 Oct 2025
Major Breast Cancer Trial Expansion: Greenwich LifeSciences Adds Belgium to Global Phase III Study - Stock Titan
Tue, 30 Sep 2025
9,065 Annual Breast Cancer Cases: Greenwich LifeSciences Expands Critical Phase III Trial to Portugal - Stock Titan
Tue, 30 Sep 2025
Greenwich LifeSciences Expands FLAMINGO-01 Clinical Trial to Portugal for Breast Cancer Immunotherapy - Quiver Quantitative
Tue, 30 Sep 2025
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 51.2 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 1,370 (K) |
| Shares Short P.Month | 1,070 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -219.1 % |
| Return on Equity (ttm) | -492 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -7.3 |
| PEG Ratio | 0 |
| Price to Book value | 90.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.02 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|